Biopharm Industry Impacts of FDA Eliminating REMS for CAR-T Therapies

Retrieved on: 2025-06-30 17:21:41

Tags for this article:

CAR T-cell therapy

Orphan drugs

Antineoplastic drugs

Cancer treatments

Food and Drug Administration

CAR T cell

B-cell maturation antigen

Cell therapy

Axicabtagene ciloleucel

Risk Evaluation and Mitigation Strategies

Bristol-Myers Squibb

Lisocabtagene maraleucel

Click the tags to see associated articles and topics

Biopharm Industry Impacts of FDA Eliminating REMS for CAR-T Therapies. View article details on hiswai:

Excerpt

FDA's action will have wide-reaching implications for the biopharma industry. Removing the REMS program may help decentralize CAR-T administration ...

Article found on: www.biopharminternational.com

View Original Article